MBX Biosciences, Inc.
MBXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. With a market capitalization of $3.03B, it sits in mid-cap territory. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Market Cap
$3.03B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-15.93
EPS (TTM)
$-2.37
EPS (Fwd)
$-3.96
ROE
-33.2%
ROA
-22.1%
Cash
$418.6M
Total Debt
$3.3M
Free CF
-$53.0M
52W Change
501.6%
Annual Financials
Cash vs Debt
Where MBX stands vs its 150-day and 200-day moving averages
As of the July 20, 2026 close, MBX finished 74.34% above its 150-day moving average ($36.09) and 92.71% above its 200-day moving average ($32.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBX overbought or oversold?
At the July 20, 2026 close, MBX's RSI(14) was 65.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $418.6M in cash comfortably exceeding the $3.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$53.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -33.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, MBX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MBX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.